Alterations in serum thrombotic biomarker in patients with acute myocardial infarction
Poster Mar 24, 2015
Abdullah S. Alhomida
Background: Acute myocardial infarction (AMI) is a critical condition with a high rate of mortality and morbidity. There is a need of developing technologies for novel biomarkers or signatures discovery towards point-of-care testing for the management of AMI. The plasminogen activator system is an important defense mechanism against intravascular thrombosis. Tissue plasminogen activator (TPA) is a protein involved in the breakdown of blood clots by catalyzing the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. In a clotting situation, TPA is released from the storage pools in the endothelium and initiates fibrin breakdown. Plasminogen activator inhibitor-1 (PAI-1) functions as a principal inhibitor of TPA and hence counteracts fibrinolysis, the physiological process that degrades blood clots. The overall fibrinolytic activity is mainly determined by the balance between TPA and PAI-1 levels.
Aims: We compared the serum levels of TPA and PAI-1 in AMI patients versus healthy controls as well as a group of patients with dyslipidemia and high blood pressure risk group).
Results: Our results showed significantly higher levels of both TPA (5.2 ± 0.22 versus 2.5 ± 0.13 ng/mL) and PAI-1 (16.3 ± 0.24 versus 10.1 ± 0.17 ng/mL) in the sera of AMI patients as compared to controls whereas the risk group showed only non-significant increases.
Conclusion: A combination of these biomarkers could serve as a useful biomarker tool to assess the prognosis of AMI. (This study was supported by National Plan for Science and Technology Program by King Saud University Project Number 08-BIO571-02).
Severe Combined Immunodeficiency (SCID) caused by thymic aplasia due to a mutation in TBX1Poster
We report one of the first cases of TBX1 haploinsufficiency causing complete thymic aplasia and SCID.READ MORE
Analysis of the Effect of Aggregated β-Amyloid on Cellular Signaling Pathways Critical for Memory in Alzheimer’s DiseasePoster
Here we evaluate the ability to detect changes in phosphorylation levels of ERK and CREB following treatment with Aβ using the SH-SY5Y neuroblastoma cell line.READ MORE
Complete alignment identification of CRISPR-Cas9 genomic off-targets using Edit-R CRISPR specificity tool and a comprehensive analysis of positional mismatch tolerancePoster
A web tool that performs complete crRNA specificity checking is introduced. In addition, we evaluated positional off-targeting of the CRISPR system.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018